Alnylam Pharmaceuticals sees $1.6B to $1.725B TTR revenue in 2025 driven by AMVUTTRA expansion
Q4 2024 Management View CEO Yvonne Greenstreet highlighted 2024 as a strong year with $1.6 billion in net product revenues, achieving the upper end of the revised guidance. She emphasized the positive ...